Products

Enzymes for Research, Diagnostic and Industrial Use

NU6027

Cat No.
CEI-0885
Description
NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.
CAS No.
220036-08-8
Molecular Weight
251.28
Storage
2 years -20 centigrade Powder; 2 weeks 4 centigrade in DMSO; 6 months -80 centigrade in DMSO.
Targets
CDK1, CDK2, ATR, DNAPK
IC50
2.5 μM; 1.3 μM; 0.4 μM; 2.2 μM
Molecular Formula
C11H17N5O2
Chemical Name
2,4-Pyrimidinediamine, 6-(cyclohexylmethoxy)-5-nitroso-
Solubility
DMSO 50 mg/mL; Water <1 mg/mL; Ethanol 3 mg/mL
In vitro
NU6027 is soaked into crystals of monomeric CDK2 and the structure refined to a resolution of 1.85 Å. NU6027 (100μM) inhibits growth of human tumor cells with mean GI50 of 10 μM. NU6027 causes a reduction in the number of cells in S-phase but not G1 or G2/M in MCF7 cells. NU6027 is a potent inhibitor of cellular ATR activity with IC50 of 6.7 μM in MCF7 cells and 2.8 μM in GM847KD cells, and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner. NU6027 (10 μM) inhibits CDK2-mediated pRbT821 by 42% and pCHK1S345 by 70%. NU6027 significantly potentiates sensitivity of cisplatin (1.4-fold at 4 μM and 8.7-fold at 10 μM), doxorubicin (1.3-fold at 4 μM and 2.5-fold at 10 μM), camptothecin (1.4-fold at 4 μM and 2-fold at 10 μM) and hydroxyurea (1.8-fold at 4 μM) aganist MCF7 cells. NU6027 also potentiates 2Gy IR in a concentration-dependent manner and the cytotoxicity of camptothecin and temozolomide (a DNA methylating agent) at concentrations above and below their LC50. NU6027 (10 μM) attenuates G2/M arrest following DNA damage, inhibits RAD51 focus formation and increases the cytotoxicity of the major classes of DNA-damaging anticancer cytotoxic therapy but not the antimitotic, paclitaxel in MCF7 cells. NU6027 (4 μM) is synthetically lethal when DNA single-strand break repair is impaired either through poly(ADP-ribose) polymerase (PARP) inhibition or defects in XRCC1 in MCF7 cells.NU6027 (4 μM) increases the proportion of cell in early apoptosis to 7.5% after 48 hours treatment in EM-C11 cells compared to 1.73% in untreated cells. NU6027 (10 μM) treatment reduces survival in XRCC1 deficient OVCAR-4 cells compared to proficient cells. NU6027 enhances cytotoxicity of cisplatin in XRCC1 deficient OVCAR-3 cells compared to XRCC1 proficient cells. NU6027 enhances Cisplatin induced DSB accumulation in XRCC1 deficient OVCAR-3 cells.
Download Datasheet:



Inquiry
Realted Products
Catalog
ProductName
EC No.
CAS No.
Source
Price
CatalogCEI-0115
EC No.
CAS No.503468-95-9
Source
CatalogCEI-0300
EC No.
CAS No.779353-01-4
Source
CatalogCEI-0864
ProductNameVE-821
EC No.
CAS No.1232410-49-9
Source
CatalogCEI-1109
ProductNameSNS-032.HCL
EC No.
CAS No.345627-90-9
Source
+ See More >>
Online Inquiry
Name:
*Phone:
*E-mail Address:
Country:
Company/Institution:
*Products or Services Interested:
Quantity:
Project Description:
Our Products are Not Intended for Private Therapeutic Use!
*Verification Code:
Please input "enzymes"(case insensitive) as verification code.

Welcome! For price inquiries, please feel free to contact us through the form below through the form on the left side. We will get back to you as soon as possible.

Sitemap  Privacy Policy
Copyright ©2011 - 2017 Creative Enzymes.
Contact Us 45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-enzymes.com
Tel: 1-631-562-8517 1-631-448-7888
Fax: 1-631-938-8127
Distributors To view the contact information for a specific location, select the desired country: